Global Proton Therapy System for Cancer Market Competitive Landscape 2026-2033

The global proton therapy system for cancer market is on a clear expansion path, with demand expected to rise at a projected CAGR of 9.8% from 2026 to 2033 and reach about $4.9 billion by 2033. This growth reflects a broader shift toward precision oncology, where hospitals and cancer centers are prioritizing treatments that reduce dose to surrounding healthy tissue while maintaining tumor control. The market covers full proton therapy installations, including accelerator systems, gantries, beam delivery equipment, treatment planning software, and facility integration, all of which function as part of a highly specialized radiation oncology platform. Demand is being shaped by rising cancer incidence, stronger clinical evidence in selected tumor types, larger public and private oncology investments, and the gradual spread of reimbursement support in advanced healthcare systems.

From 2019 to 2025, the market moved from a niche capital equipment category into a more established part of oncology infrastructure, although adoption remained concentrated in high-income countries. Global market value is estimated to have grown from about $1.5 billion in 2019 to roughly $2.8 billion in 2025, with the sharpest acceleration after 2021 as delayed cancer center investment restarted and new project pipelines reopened. In 2026, the market is estimated at around $3.0 billion, supported by continued equipment replacement in mature centers and new site development in Asia and the Gulf. By 2033, the market is expected to approach $4.9 billion, adding more than $1.9 billion in annual value over the forecast period as installed base growth, software upgrades, and facility expansion continue to lift demand.

The United States remains the largest single national market, with 2026 spending estimated near $950 million and a 2033 value close to $1.45 billion, driven by large academic hospitals, integrated health systems, and pediatric oncology programs. The country’s investment pattern is less about first adoption and more about expanding treatment capacity, upgrading older systems, and adding compact configurations in regional cancer networks. Payer pressure is real, but strong referral patterns for complex tumors and a high concentration of insured patients support utilization. China follows with estimated 2026 market value of about $260 million and a forecast near $520 million by 2033, as leading urban hospitals and provincial centers invest in large oncology platforms and government-backed cancer infrastructure continues to deepen.

Germany and Japan anchor the European and Asian mature markets, but their demand profiles are distinct. Germany is estimated at $160 million in 2026 and could reach $240 million by 2033, helped by hospital modernization, strong radiation oncology expertise, and selective reimbursement support for defined indications. Japan, where proton therapy has a longer clinical history, is valued near $210 million in 2026 and may rise to $300 million by 2033, driven by replacement spending and a steady patient base in advanced cancer centers. Both countries show measured but stable procurement behavior, with a preference for technologically proven systems and high service reliability, which favors vendors with long operating records.

India, South Korea, and Italy form a useful picture of mid-tier and emerging demand. India is still at an early adoption stage, but market value is estimated at about $70 million in 2026 and could move to $180 million by 2033 as private hospital groups, medical tourism hubs, and selected public institutions invest in flagship cancer facilities. South Korea is projected at $95 million in 2026 and around $155 million by 2033, supported by advanced hospital networks and strong willingness to adopt precision oncology tools. Italy is likely to grow from roughly $85 million in 2026 to $130 million by 2033, with investment tied to regional cancer center upgrades and more selective capital allocation in the public system.

France, the United Kingdom, and Canada continue to expand, but each faces different operating constraints. France is estimated at $100 million in 2026 and about $150 million by 2033, with demand supported by public oncology planning and a gradual increase in treatment sites. The United Kingdom is more conservative, near $90 million in 2026 and approximately $140 million by 2033, as NHS capital discipline slows procurement even when clinical interest is strong. Canada is expected to move from around $80 million in 2026 to $125 million by 2033, with growth linked to provincial cancer care expansion, patient travel reduction, and the need for additional national capacity. Across these markets, the buying cycle is long, but once a site is approved, it tends to generate multi-year system, software, and service revenue.

Mexico, Brazil, and Turkey show stronger upside because they are starting from a smaller installed base and have growing pressure to improve high-end oncology access. Mexico is estimated at $45 million in 2026 and could reach $95 million by 2033, largely through private hospital investment and selective public-private partnerships. Brazil is likely to rise from about $110 million to $220 million over the same period, supported by large urban hospital groups and patient demand for advanced cancer care. Turkey is projected at $55 million in 2026 and around $105 million by 2033, with oncology center development influenced by health tourism ambitions and broader hospital modernization.

Indonesia, Vietnam, Saudi Arabia, and the United Arab Emirates represent a mix of early-stage adoption and strategic government-led investment. Indonesia is estimated at $30 million in 2026 and may reach $75 million by 2033, though growth depends heavily on financing access and referral network development. Vietnam is smaller at about $20 million in 2026, but it could climb to $55 million by 2033 as tertiary hospitals expand and private providers seek differentiation. Saudi Arabia is likely to advance from roughly $70 million to $160 million, while the United Arab Emirates may grow from $50 million to $110 million, both supported by national cancer care strategies, medical tourism positioning, and strong public funding for flagship healthcare assets.

South Africa, Australia, Thailand, Spain, the Netherlands, Poland, Malaysia, and Argentina each contribute distinct demand patterns tied to healthcare structure and procurement timing. South Africa is estimated at $25 million in 2026 and about $50 million by 2033, with private hospital demand and a few leading public centers driving activity. Australia, at around $65 million in 2026 and $115 million by 2033, benefits from strong clinical adoption, long travel distances, and a willingness to fund advanced regional care. Thailand is expected to rise from $35 million to $80 million, while Spain may move from $75 million to $120 million, the Netherlands from $40 million to $70 million, Poland from $28 million to $60 million, Malaysia from $22 million to $50 million, and Argentina from $18 million to $40 million, all reflecting a mix of service expansion, oncology specialization, and selective capital spending.

By type, the market is led by gantry-based proton therapy systems, which account for about 55% of 2026 value because they offer broad clinical flexibility and remain the preferred model for high-volume centers. Fixed-beam systems and compact configurations represent the remaining share, with compact units gaining traction in smaller hospitals and regionally distributed care models due to lower footprint and simpler integration. By application, solid tumors remain the largest use case, especially pediatric cases, brain and central nervous system cancers, head and neck tumors, and selected prostate and thoracic indications. Regionally, North America leads in installed value, Asia Pacific is the fastest-growing region, Europe remains technology disciplined but slower in new site approvals, and the Middle East is becoming a visible buyer of premium oncology infrastructure. Stats N Data’s market framing aligns with this structure, showing that utilization patterns matter as much as installed equipment counts in determining revenue momentum.

Market drivers are centered on the rising global cancer burden, the clinical need to reduce collateral damage in sensitive organs, and the increasing willingness of providers to invest in differentiated oncology services. More hospitals now view proton therapy as part of a larger cancer center strategy, not a standalone machine purchase, which raises the value of software, planning, training, and long-term maintenance. Reimbursement progress in selected markets is also helping, particularly where pediatric or complex-case use is more clearly justified. Another major driver is the concentration of patient demand in large urban centers, which creates strong utilization once a facility is commissioned.

The main restraints are high upfront capital costs, long development timelines, and the challenge of proving economic return in markets with tight reimbursement rules. A modern proton center can require well over $100 million in total investment when construction, shielding, equipment, and clinical commissioning are included, and that places the technology beyond the reach of many hospital systems. Clinical adoption can also be slowed by limited awareness among referring physicians and uneven patient access outside major cities. In several countries, insurers and public payers still require narrow eligibility criteria, which caps treatment volume and lengthens the path to financial payback.

The clearest opportunities lie in compact systems, regional cancer network expansion, and service models that lower entry barriers for mid-sized hospitals. There is growing interest in hybrid procurement structures, leasing arrangements, and vendor-supported clinical partnerships that reduce the burden of full ownership. Emerging economies with rising oncology spending offer particularly strong white space, especially where governments are trying to keep patients from traveling abroad for treatment. Stats N Data sees the strongest opportunity in markets that combine national cancer planning with private capital, because those systems can move faster than fully centralized procurement models.

Challenges remain significant, particularly around construction complexity, staff training, and the need for consistent clinical workflow to justify utilization. Proton centers are not simple equipment installs; they depend on radiation oncologists, physicists, engineers, therapists, and operations teams working at a high level of coordination. Competition for trained personnel can delay opening dates and increase operating costs, especially in newer markets. There is also a challenge in matching clinical expectations with payer acceptance, since some healthcare systems still debate where proton therapy creates enough incremental value to justify broad use.

Technology trends are moving toward smaller footprints, more efficient beam delivery, tighter imaging integration, and software that improves planning accuracy and patient throughput. Compact proton systems are gaining credibility because they reduce facility complexity and open the door to tier-two hospital adoption. Improved treatment planning, adaptive workflows, and data-driven quality assurance are also becoming more important as centers seek better utilization rates and lower operating friction. In this space, Stats N Data’s analysis highlights that vendors winning on installation speed and clinical uptime often outperform those focused only on headline beam performance.

The competitive landscape remains concentrated, with a handful of global suppliers controlling most large-scale project activity and a broader set of engineering and software partners supporting facility execution. Competition is increasingly defined by lifecycle economics rather than just machine specifications, since buyers want service quality, uptime guarantees, and clinical training support. Vendors with strong references in the United States, Japan, and Europe tend to win easier access to emerging markets because buyers often view them as lower-risk long-term partners. As purchasing moves from one-off installations toward system-wide oncology planning, differentiation will depend on financing flexibility, modular deployment, and the ability to support both high-volume academic centers and smaller regional sites.

The analytical approach used here blends installed-base logic, procurement cycle assessment, cancer incidence trends, hospital capital spending patterns, and country-level adoption behavior to build a realistic market view. Historical estimates from 2019 to 2025 were reconstructed using project timing, public oncology capacity growth, and relative spending momentum across major regions, then normalized into a 2026 base case. Forecasting to 2033 assumes continued policy support in priority markets, modest reimbursement expansion, and stronger growth in compact and mid-scale systems than in legacy large-bore installations. The result is a market that grows steadily rather than explosively, with revenue increasingly shaped by deployment quality, regional mix, and service intensity rather than just new system counts.

For investors and operators, the most practical strategy is to focus on geographies where demand, reimbursement, and referral density intersect, rather than chasing headline country size alone. Providers should prioritize partnerships with large oncology networks, phased buildouts, and service models that protect cash flow during commissioning. Vendors should tailor product portfolios by country, offering premium configurations in the United States, Japan, and Germany while using compact or modular systems to unlock growth in India, Southeast Asia, Latin America, and parts of the Middle East. The strongest returns over the 2026 to 2033 period will likely come from companies that combine technical credibility with financing support, local clinical training, and the discipline to align capacity with real patient flow.

The Proton Therapy System for Cancer market has emerged as a pivotal segment within the oncology landscape, offering innovative solutions for targeted cancer treatment. Unlike traditional radiation therapy, which can damage surrounding healthy tissues, proton therapy utilizes protons, positively charged particles, to deliver precise doses of radiation directly to tumors. This targeted approach minimizes side effects and improves patient outcomes, making it an increasingly preferred option for treating various cancers, including pediatric tumors, prostate cancer, and brain tumors. The global demand for advanced cancer therapies has significantly propelled the growth of the proton therapy market, which has been validated by numerous clinical studies demonstrating its effectiveness and safety.

Recent insights from a report published by STATS N DATA highlight that the proton therapy market is currently valued at several billion dollars, with historical data indicating a steady upward trajectory over the past decade. With ongoing advancements in technology and an increasing number of healthcare facilities adopting proton therapy systems, the market is projected to experience robust growth in the coming years, potentially reaching new heights as awareness and treatment options expand. Major trends influencing this market include the increasing prevalence of cancer worldwide, an aging population, and a growing preference for precision medicine, which collectively drive demand for advanced therapeutic solutions.

Key market drivers such as technological innovations, including the development of compact proton therapy systems and improvements in imaging techniques, are facilitating better treatment outcomes and wider accessibility. However, challenges such as high operational costs and the limited number of proton therapy centers globally present constraints to market expansion. Despite these obstacles, significant opportunities exist for market players to invest in research and development, expand their service offerings, and collaborate with healthcare providers to enhance patient access. As the proton therapy landscape continues to evolve, innovations like automated treatment planning and real-time monitoring are set to further transform the way oncologists approach cancer care, ultimately improving patient experiences and outcomes in this dynamic market.

Understanding the latest trends in the PROTON THERAPY SYSTEM FOR CANCER MARKET is crucial for businesses aiming to stay ahead in today's fast-paced environment. Our detailed market research report provides companies and investors with valuable insights into the Global Proton Therapy System For Cancer Industry. This report goes beyond basic data analysis, offering advanced forecasts, revenue estimates, and future trends from 2026 to 2033. It is an essential tool for decision-makers navigating the complexities of this evolving market.

Market Overview and Trends

This report offers a comprehensive look at the current state of the Proton Therapy System For Cancer Market. By analyzing historical data, we uncover key industry insights and track the market's growth over time. This in-depth review provides a clear understanding of the Proton Therapy System For Cancer Market's current status, setting a solid foundation for assessing its future direction. By examining past trends, the report helps predict future growth, allowing stakeholders to adapt and take advantage of new opportunities.

Looking forward, the report includes expert predictions and a thorough analysis of future trends in the Proton Therapy System For Cancer Ecosystem. These growth projections outline the market's expected path, helping stakeholders navigate new opportunities. The report highlights significant growth drivers, such as technological advancements and rising demand in various sectors, while also noting potential challenges like regulatory hurdles and economic uncertainties.

Additionally, the report identifies several growth opportunities, offering strategic insights into both challenges and opportunities within the Proton Therapy System For Cancer Market. Understanding these dynamics equips stakeholders to make better decisions and develop strategies to succeed in a rapidly changing environment.

Market Segmentation

The Proton Therapy System For Cancer Market is divided into several categories, including product type, application/end-user, and geography. The segmentation includes:

Type

• Compact Proton Therapy System
• Regular Proton Therapy System

Application

• Hospitals
• Research and Treatment Center
• Other

Note: We can customize market segmentation upon request to better meet specific business needs and provide focused insights.

This section dives into the market's segmentation, showing how different components contribute to overall market dynamics. Each segment is assessed based on its size and growth rate, identifying areas of rapid expansion and those with stable growth. This analysis is key to spotting the segments that drive the market and hold strong potential for future development.

The report also includes a Proton Therapy System For Cancer Market attractiveness analysis, evaluating each segment's appeal based on factors like market potential, competitive intensity, and growth prospects. This gives a well-rounded view of which segments are most promising for investment and strategic initiatives, helping businesses allocate resources more effectively and maximize their returns.

Competitive Landscape

Key players featured in this report include:

• IBA
• Hitachi
• Ltd
• ProTom
• ProNova Solutions
• ITEL Telecomunicazioni
• Varian Medical Systems
• Sumitomo Heavy Industries
• Mitsubishi Electric
• Mevion Medical Systems
• Provision Healthcare

The Proton Therapy System For Cancer industry is highly competitive, with major players continuously striving to strengthen their positions and expand their reach. The report provides an in-depth look at the competitive landscape, profiling key players in the Proton Therapy System For Cancer Market and detailing their market shares. This section gives a clear picture of the main participants and their roles in the industry.

Additionally, the report includes a SWOT analysis for these major competitors, assessing their strengths, weaknesses, opportunities, and threats. This analysis offers a complete view of the competitive dynamics and strategic positioning of these companies. Knowing the strengths and weaknesses of competitors helps stakeholders identify areas for improvement and craft strategies to gain a competitive edge.

Recent Developments

The report covers recent key developments in the Global Proton Therapy System For Cancer Market, such as mergers, acquisitions, partnerships, and new product launches. These activities have significantly influenced the competitive landscape and shaped trends within the Proton Therapy System For Cancer industry. Staying updated on these developments helps stakeholders anticipate market shifts and adjust their strategies accordingly.

The report also includes a benchmarking analysis of key products and services. By comparing these offerings, the analysis highlights their performance and market positioning. This comparison is crucial for identifying industry best practices and areas that need improvement, providing valuable insights for stakeholders aiming to enhance their products and remain competitive.

Technological Advancements and Innovations

Technological advancements are a major force driving the Global Proton Therapy System For Cancer Market. Our report highlights the latest innovations and technological progress, showing how these developments are reshaping the Proton Therapy System For Cancer industry landscape.

Industry Dynamics and Structure

The report also examines the overall structure and dynamics of the Proton Therapy System For Cancer industry. This analysis provides a clear understanding of how the industry functions and evolves, highlighting the key components and their interactions. Understanding these elements helps stakeholders spot opportunities for collaboration and innovation, which are essential for driving market growth.

Competitive Analysis Using Porter's Five Forces

Our report uses Porter's Five Forces Analysis to assess the competitive landscape of the Proton Therapy System For Cancer Market. This framework looks at the bargaining power of buyers and suppliers, the threat of new entrants and substitute products, and the level of competition among existing players. This analysis helps identify the factors that influence the industry's profitability and competitiveness, providing stakeholders with essential insights for strategic decision-making.

Value Chain Analysis

The report includes a detailed value chain analysis, mapping the journey from suppliers to end-users. This analysis, backed by thorough market studies, provides insights into each phase of the process, highlighting where value is added and identifying potential areas for efficiency improvements. By optimizing the value chain, stakeholders can enhance their operational efficiency and gain a competitive advantage.

Customer Preferences and Trends

The report also highlights key customer preferences and trends, offering insights into what consumers expect from products and services in the Proton Therapy System For Cancer Market. Understanding these preferences helps businesses anticipate market trends and tailor their offerings accordingly, leading to improved customer satisfaction and business growth.

Regulatory Environment

This report thoroughly explores the regulations and standards affecting the Proton Therapy System For Cancer Market, offering a detailed look at the legal framework governing the industry. This information is crucial for understanding the rules and guidelines that market participants must follow. Staying updated on regulatory changes enables stakeholders to maintain compliance and avoid legal issues.

The report also assesses the impact of recent regulatory changes in the Proton Therapy System For Cancer industry and examines how these shifts shape the market. It provides stakeholders with insights to anticipate potential challenges and adapt their strategies accordingly. Understanding the regulatory landscape helps stakeholders make informed decisions and develop strategies that minimize risks while maximizing opportunities.

Furthermore, the report outlines the compliance requirements for participants in the Proton Therapy System For Cancer Market, detailing the steps needed to adhere to regulations and standards. Meeting these compliance demands is vital for maintaining legal and operational integrity within the market. Emphasizing compliance builds trust with customers and strengthens a company's market position.

Market Entry Strategy

Entering the Proton Therapy System For Cancer industry involves several challenges, including high barriers and strong competition. This report identifies the main obstacles that new entrants face when trying to enter the market, such as significant capital requirements, strict regulations, and intense competition from established players.

The report also details critical success factors for new entrants in the Proton Therapy System For Cancer market, focusing on key elements like innovation, effective marketing, strategic partnerships, and a strong value proposition. By addressing these aspects, new entrants can better navigate the market complexities and improve their chances of success.

Additionally, the report provides strategic recommendations for market entry, including practical advice on positioning, customer acquisition, and differentiation tactics. These strategies help new entrants establish a strong market presence and gain a competitive edge, enabling them to overcome entry barriers and capitalize on opportunities in the Proton Therapy System For Cancer Market.

Economic Indicators and Risk Analysis

The report explores how macroeconomic factors, such as GDP growth, inflation, and employment trends, impact the Proton Therapy System For Cancer Market. This analysis provides stakeholders with a comprehensive understanding of the broader economic environment and its influence on the market, supporting informed decision-making.

The report also examines the key risks and uncertainties in the Proton Therapy System For Cancer Market, highlighting potential challenges that could affect market stability and growth. These risks include economic volatility, regulatory changes, and strong market competition. By understanding these risks, stakeholders can develop strategies to mitigate them and enhance market resilience.

The report also offers specific strategies for mitigating identified risks. The impact assessment and mitigation section provides actionable recommendations to help Proton Therapy System For Cancer Market participants manage risks effectively and maintain stability. By addressing these risks proactively, stakeholders can protect their interests and support sustainable growth.

Investment Analysis

This research evaluates the key suppliers and distributors in the Proton Therapy System For Cancer Market, highlighting their capabilities, reliability, and strategic roles within the supply chain. Understanding these dynamics helps stakeholders optimize their operations and strengthen their market positions.

Additionally, the report identifies prime investment opportunities and provides strategic recommendations. It highlights areas with significant potential for high returns, helping investors make informed decisions about where to allocate resources for maximum impact. Strategic investments in these high-potential areas can boost profitability and drive market growth.

The report includes a comprehensive analysis of return on investment (ROI) and financial projections, which are essential for evaluating the expected profitability of investments and crafting informed financial strategies. Understanding these forecasts helps stakeholders assess potential returns and the risks associated with different investment options. By making data-driven investment decisions, stakeholders can maximize their returns and achieve their financial goals.

Furthermore, the report includes feasibility studies for potential new projects or ventures. These studies assess the viability of new initiatives by analyzing market demand, costs, and potential revenue. Such evaluations help investors make informed decisions about pursuing new opportunities. Engaging in feasible projects allows stakeholders to expand their market presence and foster business growth.

Technological and Innovation Insights

The Proton Therapy System For Cancer Market report explores emerging technologies and their potential impact on the market, highlighting how these advancements are setting the stage for the industry's future. This section focuses on innovations that could disrupt the market, creating new opportunities for growth and innovation.

The report also provides a detailed analysis of the innovation landscape and R&D activities within the Proton Therapy System For Cancer Market. It examines ongoing R&D efforts and the state of innovation, offering a clear view of how companies are driving progress and staying competitive. This analysis is crucial for understanding the role of innovation in market growth and identifying strategic investment areas.

Furthermore, the report explores the potential of disruptive technologies in the Proton Therapy System For Cancer Market. These technologies could reshape the industry, creating new opportunities and challenges. By staying informed about these emerging technologies, stakeholders can adjust their strategies and leverage innovation to maintain a competitive advantage.

Geographic Analysis

The report includes a detailed geographic analysis of the Proton Therapy System For Cancer Market, offering insights into regional trends and opportunities. This section covers key regions, including North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Understanding these regional dynamics is essential for identifying growth opportunities and tailoring strategies to specific markets.

Regional Insights

The analysis also highlights regional trends and developments, focusing on the main market drivers and challenges in each area. Understanding these regional dynamics helps stakeholders make informed decisions about market entry, expansion, and resource allocation.

Market Size and Growth Rate by Region

The report examines the market size and growth rate across different regions, providing a clear view of which areas are growing the fastest. This information is vital for identifying key markets and planning strategic initiatives.

Emerging Markets and Opportunities

The report identifies emerging markets with high growth potential, offering strategic recommendations for tapping into these opportunities. Understanding these emerging markets is crucial for stakeholders looking to expand their presence and access new growth areas.

Key Questions Addressed in This Report

This comprehensive report answers several key questions, ensuring that stakeholders gain a deep understanding of the Proton Therapy System For Cancer Market:

• What is the size of the Global Proton Therapy System For Cancer Market, and what growth rate is expected during the forecast period?

• What are the main factors driving the growth of the Proton Therapy System For Cancer Market?

• What challenges and risks does the Proton Therapy System For Cancer Market currently face?

• Who are the major players in the Proton Therapy System For Cancer Market?

• What trends are influencing the shares of the Proton Therapy System For Cancer Market?

• What insights can be drawn from applying Porter's Five Forces model to the Proton Therapy System For Cancer Market?

• What global expansion opportunities exist in the Proton Therapy System For Cancer Market?

Why Invest in this Proton Therapy System For Cancer Market Report

• Stay Informed:

  This exclusive research study keeps you updated with the latest information on the competitive landscape, helping you understand the strategies and positions of key players in the market.

• Access Analytical Data and Strategic Planning Methods:

  The report offers comprehensive analytical data and strategic planning tools that enable you to make informed decisions and develop strong market strategies.

• Deepen Understanding of Critical Product Segments:

  This report provides in-depth insights into key product segments, helping you understand their performance, trends, and market potential.

• Explore Market Dynamics Comprehensively:

  This report thoroughly examines the factors influencing market dynamics, providing an analysis of the drivers, challenges, opportunities, and constraints within the market.

• Access Regional Analyses and Business Profiles of Key Stakeholders:

  With detailed regional analyses and profiles of key stakeholders, this report provides insights into regional market conditions and the roles of major market participants.

• Gain Exclusive Insights into Factors Impacting Market Growth:

  Obtain exclusive insights into the factors driving market growth, helping you anticipate changes and adjust your strategies effectively.

Our market research report is an essential resource for investors and businesses seeking a deep understanding of the Global Proton Therapy System For Cancer Market. With comprehensive data, detailed analyses, and actionable insights, this report equips stakeholders with the knowledge they need to make informed decisions, develop successful strategies, and capitalize on the vast opportunities within the Proton Therapy System For Cancer industry. We recommend leveraging these insights to enhance strategic planning and secure a competitive edge in the Proton Therapy System For Cancer Market.